2型糖尿病肾功能正常或轻度受损患者中FGF23与死亡率的关联
研究分析310例2型糖尿病且eGFR≥60 mL/min/1.73 m2患者的C端FGF23水平,随访5.8年(3.3-6.5)期间47例发生MACE、28例死亡;FGF23与全因死亡(年龄和性别校正HR 2.78 [95%CI 1.76-4.40])及MACE(1.67 [1.12-2.49])风险升高相关,额外校正及独立队列重复后结果一致。
要点
- FGF23与2型糖尿病肾功能正常或轻度受损患者全因死亡风险升高相关。
- FGF23与主要不良心血管事件(MACE)风险升高相关。
- 关联在多因素校正及独立队列重复后仍一致。
核心结论
- 在2型糖尿病且肾功能正常或轻度受损患者中,FGF23与心血管事件和死亡风险升高相关。
研究设计与样本
- 分析310例2型糖尿病且eGFR≥60 mL/min/1.73 m2患者的C端FGF23水平。
- 采用Cox回归研究FGF23与全因死亡及MACE的关联。
- 随访5.8年(3.3-6.5),期间47例发生MACE、28例死亡。
主要发现
- FGF23与全因死亡风险升高相关,年龄和性别校正HR 2.78(95%CI 1.76-4.40)。
- FGF23与MACE风险升高相关,年龄和性别校正HR 1.67(95%CI 1.12-2.49)。
- 额外校正其他潜在混杂因素后结果相似。
- 在独立队列中重复后结果一致。
临床怎么用
- 在2型糖尿病肾功能正常或轻度受损患者中,FGF23或有助于识别心血管事件和死亡高风险者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study whether fibroblast growth factor 23 (FGF23) is associated with adverse outcomes in patients with type 2 diabetes and normal or mildly impaired kidney function. RESEARCH DESIGN AND METHODS: We analyzed C-terminal FGF23 levels in 310 patients with type 2 diabetes and estimated glomerular filtration rate ≥60 mL/min/1.73 m2. Associations of FGF23 with all-cause mortality and major adverse cardiovascular events (MACE) were studied by Cox regression. RESULTS: During a follow-up of 5.8 years (3.3-6.5), 47 patients developed MACE and 28 patients died. FGF23 was associated with an increased risk of all-cause mortality (age- and sex-adjusted hazard ratio 2.78 [95% CI 1.76-4.40]) and MACE (1.67 [1.12-2.49]). Results were similar after additional adjustment for other potential confounders and were consistent upon replication in an independent cohort. CONCLUSIONS: In patients with type 2 diabetes and normal or mildly impaired kidney function, FGF23 is associated with an increased risk of cardiovascular events and mortality.
引用
- Yeung SMH, Binnenmars SH, Gant CM, et al. Fibroblast Growth Factor 23 and Mortality in Patients With Type 2 Diabetes and Normal or Mildly Impaired Kidney Function. Diabetes Care. 2019. PMID: 31488569. doi:10.2337/dc19-0528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。